{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.4","upperLimit":"62.0","value":"37.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Patients were evaluated for the development of acute GVHD within the first 100 days post HSCT. The cumulative incidence of grade II-IV acute GVHD was determined using competing risk analysis. Competing risks for acute GVHD were death and nonengraftment.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients were analyzed as a single population. Stratification by conditioning regimen was not done.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 Days Post Hematopoietic Stem Cell Transplant (HSCT)","title":"Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100","type":"PRIMARY","unitOfMeasure":"Percentage of patients developing aGVHD"}